+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2024

  • ID: 4852025
  • Report
  • Region: Global
  • 176 pages
  • Transparency Market Research
1 of 2

Global Scleroderma Diagnostics and Therapeutics Market: Overview

The scleroderma diagnostics and therapeutics market report studies the scleroderma diagnostics and therapeutics market globally as well as regionally for the forecast period from 2017 to 2024. The report provides valuable insights into the growth of the said market, wherein revenue estimates are presented in US$ Mn and volume estimates in Kilo tons.

Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various scleroderma drugs as well as new entrants planning to enter this market.

Included in the study is a detailed discussion on vital market indicators, which include demand drivers, challenges, and opportunities. The impact of these indicators on the scleroderma diagnostics and therapeutics market over the aforementioned forecast period have been ascertained as well. Furthermore, the report also examines growth trends and technological advancements that are likely to have a bearing on the growth of scleroderma diagnostics and therapeutics market between 2017 and 2024.

Following this, the report discusses value chain analysis to throw light on demand supply dynamics in the scleroderma diagnostics and therapeutics market. Industry-centric analytical tools such as SWOT analysis and Porter’s five forces have been employed for insights into the competitive landscape of the scleroderma diagnostics and therapeutics market. In addition, the report presents market attractiveness analysis wherein key segments within drug class, indication, test type, and geography have been identified and analyzed for their growth behavior.

Global Scleroderma Diagnostics and Therapeutics Market: Research Methodology

The report has been prepared after an elaborate primary and secondary research phase. Thus, the analysis of the scleroderma diagnostics and therapeutics market presented in reliable to a high degree. The primary research phase involved carrying out telephonic as well face-to-face interviews with industry experts along with e-mail interactions. Primary research represent major part of research efforts along with a secondary research phase. Industry stakeholders who participated in the primary research phase include CEOs, VPs, market intelligence managers, marketing/product managers, and national sales managers. Purchasing managers, technical experts, suppliers and traders were some other stakeholders who were reached out in the primary research phase. Rheumatologists, dermatologists, and physicians treating scleroderma patients were also reached out in the primary research phase of the making of the report.

Secondary research phase involved reaching out to industry-centric databases for data collection followed by data scrutiny. Secondary sources reached out include key players’ product literature, annual reports, relevant business documents, and trade journals. Some other secondary sources reached out include trade journals, technical writings, government websites, trade associations, Internet sources, and online paid databases.

Secondary research sources reached out for the study include stock analyst websites, company website sources, governmental organizations and public portals, Orange Book – FDA, U.S. Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, Clinicaltrials.gov, Clinicaltrialsregister.eu, journals and other publications.

Note: Product cover images may vary from those shown
2 of 2
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecasts, 2014-2024
4.5. Scleroderma Diagnostics and Therapeutics Market Outlook
4.6. Scleroderma : Overview of Clinical Trials

Chapter 5. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Indication
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
5.3.1. Localized
5.3.2. Systemic
5.4. Market Attractiveness Analysis, by Indication, 2015
5.5. Key Trends and Developments

Chapter 6. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class
6.3.1. Corticosteroids
6.3.2. Immunosuppressive Agents
6.3.3. Endothelin receptor antagonists
6.3.4. Calcium Channel Blockers
6.3.5. PDE-5 Inhibitors
6.3.6. Chelating Agents
6.3.7. Prostacyclin analogues
6.3.8. Others
6.4. Market Attractiveness Analysis, by Drug Class, 2015
6.5. Key Trends and Developments

Chapter 7. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis, by Region, 2015
7.5. Key Trends

Chapter 8. North America Scleroderma Therapeutics Market Analysis and Forecast
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Indication
8.3.1. Localized
8.3.2. Systemic
8.4. Market Size (US$ Mn) Forecast, by Drug Class
8.4.1. Corticosteroids
8.4.2. Immunosuppressive Agents
8.4.3. Endothelin receptor antagonists
8.4.4. Calcium Channel Blockers
8.4.5. PDE-5 Inhibitors
8.4.6. Chelating Agents
8.4.7. Prostacyclin analogues
8.4.8. Others
8.5. Market Size (US$ Mn) Forecast, by Country
8.5.1. U.S.
8.5.2. Canada
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Market Attractiveness Analysis, by Drug Class, 2015
8.8. Key Trends

Chapter 9. Europe Scleroderma Therapeutics Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Indication
9.3.1. Localized
9.3.2. Systemic
9.4. Market Size (US$ Mn) Forecast, by Drug Class
9.4.1. Corticosteroids
9.4.2. Immunosuppressive Agents
9.4.3. Endothelin receptor antagonists
9.4.4. Calcium Channel Blockers
9.4.5. PDE-5 Inhibitors
9.4.6. Chelating Agents
9.4.7. Prostacyclin analogues
9.4.8. Others
9.5. Market Size (US$ Mn) Forecast, by Country
9.5.1. U.K.
9.5.2. Germany
9.5.3. France
9.5.4. Rest of Europe
9.6. Market Attractiveness Analysis, by Indication 2015
9.7. Market Attractiveness Analysis, by Drug Class, 2015
9.8. Key Trends

Chapter 10. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Indication
10.3.1. Localized
10.3.2. Systemic
10.4. Market Size (US$ Mn) Forecast, by Drug Class
10.4.1. Corticosteroids
10.4.2. Immunosuppressive Agents
10.4.3. Endothelin receptor antagonists
10.4.4. Calcium Channel Blockers
10.4.5. PDE-5 Inhibitors
10.4.6. Chelating Agents
10.4.7. Prostacyclin analogues
10.4.8. Others
10.5. Market Size (US$ Mn) Forecast, by Country
10.5.1. China
10.5.2. India
10.5.3. Japan
10.5.4. Rest of Asia Pacific
10.6. Market Attractiveness Analysis, by Indication, 2015
10.7. Market Attractiveness Analysis, by Drug Class, 2015
10.8. Key Trends

Chapter 11. Latin America Scleroderma Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product
11.3.1. Localized
11.3.2. Systemic
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
11.4.1. Corticosteroids
11.4.2. Immunosuppressive Agents
11.4.3. Endothelin receptor antagonists
11.4.4. Calcium Channel Blockers
11.4.5. PDE-5 Inhibitors
11.4.6. Chelating Agents
11.4.7. Prostacyclin analogues
11.4.8. Others
11.5. Market Size (US$ Mn) Forecast, by Country
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Rest of Latin America
11.6. Market Attractiveness Analysis, by Indication, 2015
11.7. Market Attractiveness Analysis, by Drug Class, 2015
11.8. Key Trends

Chapter 12. Middle East & Africa Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Indication
12.3.1. Localized
12.3.2. Systemic
12.4. Market Size (US$ Mn) Forecast, by Drug Class
12.4.1. Corticosteroids
2.4.2. Immunosuppressive Agents
12.4.3. Endothelin receptor antagonists
12.4.4. Calcium Channel Blockers
12.4.5. PDE-5 Inhibitors
12.4.6. Chelating Agents
12.4.7. Prostacyclin analogues
12.4.8. Others
12.5. Market Size (US$ Mn) Forecast, by Country
12.5.1. UAE
12.5.2. South Africa
12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis, by Indication, 2015
12.7. Market Attractiveness Analysis, by Drug Class, 2015
12.8. Key Trends

Chapter 13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
13.2.1. Actelion Pharmaceuticals, Inc.
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Financial Overview
13.2.1.3. Product Portfolio
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Bayer AG
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Financial Overview
13.2.2.3. Product Portfolio
13.2.2.4. SWOT Analysis
13.2.2.5. Strategic Overview
13.2.3. Boehringer Ingelheim
13.2.3.1. Company Overview (HQ, business segments, employee strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Financial Overview
13.2.3.5. Strategic Overview
13.2.4. Corbus Pharmaceutical Holdings, Inc.
13.2.4.1. Company Overview (HQ, business segments, employee strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Strategic Overview
13.2.4.5. Key Developments
13.2.5. Cumberland Pharmaceuticals Inc.
13.2.5.1. Company Overview (HQ, business segments, employee strength)
13.2.5.2. Financial Overview
13.2.5.3. Product Portfolio
13.2.5.4. SWOT Analysis
13.2.5.5. Strategic Overview
13.2.6. Cytori Therapeutics, Inc.
13.2.6.1. Company Overview (HQ, business segments, employee strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Financial Overview
13.2.6.5. Strategic Overview
13.2.7. F. Hoffmann La Roche Ltd.
13.2.7.1. Company Overview (HQ, business segments, employee strength)
13.2.7.2. Financial Overview
13.2.7.3. Product Portfolio
13.2.7.4. SWOT Analysis
13.2.7.5. Strategic Overview
13.2.8. Gilead Sciences, Inc.
13.2.8.1. Company Overview (HQ, business segments, employee strength)
13.2.8.2. Financial Overview
13.2.8.3. Product Portfolio
13.2.8.4. SWOT Analysis
13.2.8.5. Strategic Overview
13.2.9. Merck KGaA
13.2.9.1. Company Overview (HQ, business segments, employee strength)
13.2.9.2. Product Portfolio
13.2.9.3. Financial Overview
13.2.9.4. SWOT Analysis
13.2.9.5. Strategic Overview
13.2.10. Pfizer, Inc.
13.2.10.1. Company Overview (HQ, business segments, employee strength)
13.2.10.2. Product Portfolio
13.2.10.3. Financial Overview
13.2.10.4. SWOT Analysis
13.2.10.5. Strategic Overview
13.2.11. Sanofi
13.2.11.1. Company Overview (HQ, business segments, employee strength)
13.2.11.2. Product Portfolio
13.2.11.3. Financial Overview
13.2.11.4. SWOT Analysis
13.2.11.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll